Gantchev T G, Brasseur N, van Lier J E
Department of Nuclear Medicine and Radiobiology, Faculty of Medicine, University of Sherbrooke, QC, Canada.
Br J Cancer. 1996 Nov;74(10):1570-7. doi: 10.1038/bjc.1996.591.
Etoposide (VP-16) is an anti-cancer drug commonly used against several types of tumours and leukaemia, either alone or in combination chemotherapy. Photodynamic therapy (PDT) is another, relatively new modality for treatment of various malignancies. The interactions between VP-16 and PDT, using aluminium tetrasulphophthalocyanine as photosensitiser, in K562 human leukaemic cells were investigated. Cell responses to individual and combined drug treatment under different experimental conditions revealed synergistic drug toxicity. The latter was evident from various events of cell response, including supra-additive accumulation of cells in G2/M cell cycle phase and endonucleolytic DNA fragmentation (apoptosis). The involvement of the cellular antioxidant system in the synergistic interactions of photosensitisation and VP-16 is proposed.
依托泊苷（VP - 16）是一种抗癌药物，常用于治疗多种类型的肿瘤和白血病，可单独使用或用于联合化疗。光动力疗法（PDT）是另一种相对较新的治疗各种恶性肿瘤的方法。研究了在K562人白血病细胞中，以四磺基铝酞菁作为光敏剂时，VP - 16与PDT之间的相互作用。在不同实验条件下，细胞对单独和联合药物治疗的反应显示出协同药物毒性。后者从细胞反应的各种事件中明显可见，包括细胞在G2/M细胞周期阶段的超相加积累和核酸内切酶介导的DNA片段化（凋亡）。有人提出细胞抗氧化系统参与了光致敏和VP - 16的协同相互作用。
